GEHC · GE HealthCare Technologies Inc.

GE HealthCare’s Q1 2026 results reflect solid top-line execution—revenue grew 7.4% YoY to $5.13 billion, with organic growth at 2.9%, led by strong performance in Pharmaceutical Diagnostics (+21.7% YoY), Imaging (+7.4%), and Advanced Visualization Solutions (+8.2%). However, profitability was materially pressured: net income declined 31% YoY to $389 million, and diluted EPS dropped 31% to $0.85, driven by a 420 bps contraction in net income margin to 7.6%. Management explicitly attributed this to three factors: tariffs, a sharp 79.8% YoY decline in Patient Care Solutions segment EBIT, and a discrete, now-resolved PDx supplier issue. Inflationary headwinds—including surging memory chip, oil, and freight costs—emerged more severely than anticipated during the quarter, prompting a downward revision to full-year guidance. Adjusted EPS outlook was narrowed and lowered to $4.80–$5.00 (4.6%–9.0% growth), down from $4.95–$5.15, and free cash flow guidance was reduced to ~$1.6 billion from ~$1.7 billion. Notably, the company reaffirmed its organic revenue growth target (3.0%–4.0%) and expects to offset over half the inflation impact via pricing and cost actions. Strategic activity included the $2.3 billion acquisition of Intelerad—closed March 18, 2026—which is expected to accelerate cloud-first enterprise imaging—and $100 million in share repurchases. While innovation momentum remains strong (e.g., FDA clearances for SIGNA MRI, Photonova Spectra CT, and View diagnostic viewer), near-term margin pressure and guidance cuts signal elevated execution risk amid persistent input cost volatility.